Danske Bank downgraded Xvivo Perfusion (XVIPF) to Sell from Buy with a price target of SEK 325, down from SEK 560. The firm sees short-term headwinds and a “too rich” valuation.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on XVIPF: